Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study
Curr Oncol. 2023 Dec 18;30(12):10509-10518. doi: 10.3390/curroncol30120766.ABSTRACTImmune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 inhibitors, have become the standard of care for many cancer types. However, they induce immune-related adverse events (irAEs), including neurotoxicity and hypophysitis. The incidence and outcomes of neurotoxicity and hypophysitis in patients treated with immune checkpoint inhibitors are not well established. We conducted a retrospective study of 812 patients with solid cancers who received immune checkpoint inhibitors at the University General Hospital of Ioannina between Janua...
Source: Current Oncology - December 22, 2023 Category: Cancer & Oncology Authors: Anna Lea Amylidi Aristeidis Gogadis Melina Yerolatsite George Zarkavelis Nanteznta Torounidou Varvara Keramisanou Eleftherios Kampletsas Davide Mauri Source Type: research
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations —going beyond the body‐size effect
This study approach may be applicable to the optimization of pediatric dosing o f other mAbs and possibly other biologics. (Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - December 20, 2023 Category: Drugs & Pharmacology Authors: Zheyi Hu,
Sihang Liu,
Yue Zhao,
Shengnan Du,
Lora Hamuro,
Jun Shen,
Amit Roy,
Li Zhu Tags: ARTICLE Source Type: research
Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
ConclusionsUndetectable ctDNA and CR on imaging after stopping immunotherapy for toxicity results in high rates of long-term durable control. For patients with immunotherapy related toxicity, who have persistent ctDNA at 8 – 12 weeks, the risk of disease progression is significant. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - December 19, 2023 Category: Cancer & Oncology Source Type: research
